Skip to main content
. 2019 Oct 9;14(10):e0223639. doi: 10.1371/journal.pone.0223639

Fig 5. The pathway “Nephrin Interactions” is highly aberrant in the GDC HNSCC cohort and Light to FDA-approved Cancer Drugs.

Fig 5

Nephrin Interactions is an example of a top-ranked light pathway, defined as a pathway highly covered with HNSCC mutations (~100%) and frequently mutated in the patient cohort (36%). Nodes in green are genes mutated in the GDC HNSCC cohort and nodes in yellow are mutated in the cohort as well annotated as targets for cancer drugs in the Cancer Targetome. Drugs are indicated by red diamonds and represent FDA-approved cancer drugs with targets in this pathway. For drug-target interactions shown here, we required supporting binding assay evidence to be <1000nM.